Remdesivir no silver bullet for COVID-19 treatment, says WHO |
Clinical News
eMediNexus Coverage from: 
Remdesivir no silver bullet for COVID-19 treatment, says WHO

0 Read Comments                

An advisory body of the World Health Organization (WHO) is not recommending the use of the antiviral drug remdesivir for hospitalized COVID-19 patients, stating that there is lack of evidence that it improves survival outcomes or decreases the need for ventilation.

A WHO Guideline Development Group (GDG) panel of international experts made the recommendation in the BMJ as part of “living guidelines” for the management of the coronavirus and assistclinicians in making better decisions in consultation with patients.

The recommendation is based on new evidence comparing the effects of multiple drugs on treating COVID-19 and includes data from four international randomized trials that included over 7,000 COVID-19 inpatients… (UN, November 19, 2020)

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now